Actualités 17.04.2024 Addex Therapeutics lance la spin-off Neurosterix à Genève avec un investissement de USD 63 millions La société genevoise Addex Therapeutics s’est associée à Perceptive Advisors pour lancer la spin-off Neurosterix, un nouvel acteur dans le dévelo...
Aktuell 30.04.2024 Johnson & Johnson eröffnet Innovation Hub in Allschwil Johnson & Johnson hat im Switzerland Innovation Park Basel Area den ersten J&J Innovation Hub auf dem europäischen Festland eröffnet. Es stellt e...
News 17.04.2024 Addex Therapeutics launches spin-off Neurosterix in Geneva with USD 63 million investment Geneva's Addex Therapeutics has teamed up with Perceptive Advisors to launch spin-off Neurosterix, a new player in neurology-focused drug develop...
News 14.02.2024 University of Fribourg discovers drug to combat age-related neuroinflammation Scientists at the University of Fribourg have uncovered a groundbreaking mechanism that could significantly mitigate age-related neuroinflammatio...
News 10.01.2024 The remarkable chemical-pharmaceutical industry in the canton of Valais For decades, the canton of Valais has cultivated a reputation for excellence in the chemical and pharmaceutical industries, combining innovation ...
News 24.05.2023 Latest research shows 20% of European biotechs now headquartered in Switzerland Press release New research conducted by IQVIA and recently published in the 2023 Swiss Biotech Report shows that 20% of European biotech companies are now head...
Aktuell 10.05.2024 BioVersys erweitert Serie-C-Runde auf 44,9 Millionen Franken BioVersys verstärkt die Zusammenarbeit mit GSK, um die Entwicklung von Alpibectir zur Behandlung von Tuberkulose zu beschleunigen. GSK beteiligt ...
News 10.05.2024 BioVersys extends Series C financing round to 44.9 million Swiss francs BioVersys is bolstering its partnership with GSK in order to accelerate the development of alpibectir for the treatment of tuberculosis. GSK is s...
Success stories 09.06.2022 La Svizzera offre condizioni interessanti e stabili per le aziende internazionali Merck Il leader scientifico e tecnologico Merck è presente in Svizzera da quasi un secolo. Oggi ha otto sedi, tra cui cinque impianti di produzione, e ...
Actualités 08.03.2021 Debiopharm signe un contrat de plus de EUR 900 millions avec Merck Debiopharm a accordé une licence mondiale exclusive au géant pharmaceutique Merck pour le développement et la commercialisation de son médicament...
News 08.03.2021 Debiopharm enters EUR 900+ million contract with Merck Debiopharm has granted a worldwide exclusive license to pharma giant Merck for the development and commercialization of its Xevinapant head and n...
News 30.04.2024 Johnson & Johnson opens Innovation Hub in Allschwil Johnson & Johnson has opened its first J&J Innovation Hub on the European mainland at the Switzerland Innovation Park Basel Area. This represents...
News 05.07.2022 CHF 178 million to further develop life sciences in the canton of Vaud To consolidate the development of life sciences in the canton of Vaud, the State Council has announced an investment of CHF 178.71 million in the...
News 31.05.2022 RetinAI enters a multi-year software license agreement with Novartis Building on their existing relationship, Bern-based RetinAI and pharma giant Novartis have entered a long-term collaboration with a multi-year so...
News 12.01.2022 ObsEva achieves positive results in the treatment of endometriosis Geneva-based women’s health biopharmaceutical company ObsEva has announced positive topline results from the Phase 3 EDELWEISS 3 trial of linzago...
News 04.04.2024 Galderma completes largest IPO on a global level in Q1 Galderma has banked nearly 2.3 billion Swiss francs following its listing on the SIX Swiss Exchange. The pharma firm was therefore responsible fo...